Sponsor: Merck
Sponsor Study ID: V940-002
Study Title: A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants with Resected Stage II, IIIA, IIIB (N2) Non-Small Cell Lung Cancer
CTO #: 103948
NCT Number: NCT06077760
Phase: III
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Lung
Study Objectives: To compare V940 plus pembrolizumab to placebo plus pembrolizumab with respect to DFS. To compare V940 plus pembrolizumab to placebo plus pembrolizumab with respect to OS. To evaluate V940 plus pembrolizumab to placebo plus pembrolizumab with respect to DMFS as assessed by the investigator.